T-Cell Immunotherapy: Looking Forward
Year: 2014
Type: article
Abstract: The rapidly expanding field of T-cell immunotherapy has experienced clinical successes along with some serious toxicities. “T Cell Immunotherapy: Optimizing Trial Design,” a workshop sponsored by the National Institutes of Health's (NIH's) Office of Biotechnology Activities (OBA), brought together researchers to discuss the scientific advances and share new data on key trial design issues, including the selection of new targets, optimizing the T-cell population, preconditioning regimens, strategies to promote persistence of cells, and analysis and management of acute reactions to T-cell infusions with the goal of identifying best practices and a research agenda that will facilitate further development and maximize the safety of this promising approach.
Source: Molecular Therapy
DOI: 10.1038/mt.2014.148
Authors: Jacqueline Corrigan-Curay, Hans-Peter Kiem, David Baltimore, Marina O'Reilly, Renier J Brentjens, Laurence Cooper, Stephen Forman, Stephen Gottschalk, Philip Greenberg, Richard Junghans, Helen Heslop, Michael Jensen, Crystal Mackall, Carl June, Oliver Press, Daniel Powell, Antoni Ribas, Steven Rosenberg, Michel Sadelain, Brian Till, Amy P Patterson, Robert C Jambou, Eugene Rosenthal, Linda Gargiulo, Maureen Montgomery, Donald B Kohn
Institutions: National Institutes of Health, Office of the Director, Fred Hutch Cancer Center, California Institute of Technology, Memorial Sloan Kettering Cancer Center, The University of Texas MD Anderson Cancer Center, City Of Hope National Medical Center, City of Hope, Baylor College of Medicine, Roger Williams Medical Center, University of Washington, National Cancer Institute, Abramson Cancer Center, University of Pennsylvania, University of California, Los Angeles
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,500
OpenAlex ID: W2026535350